Medroxyprogesterone Acetate Injectable Suspension (MEDROXYPROGESTERONE ACETATE)
Medroxyprogesterone Acetate Injectable Suspension (MEDROXYPROGESTERONE ACETATE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Medroxyprogesterone Acetate Injectable Suspension; Generic name: MEDROXYPROGESTERONE ACETATE; Manufacturer: Hikma Pharmaceuticals USA Inc..
| Brand name | Medroxyprogesterone Acetate Injectable Suspension |
|---|---|
| Generic name | MEDROXYPROGESTERONE ACETATE |
| Manufacturer | Hikma Pharmaceuticals USA Inc. |
| Used for | 1 INDICATIONS AND USAGE Medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. Medroxyprogesterone acetate injectable suspension is a progestin indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. ( 1 , 5.1 ) Limitations of Use : The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless ot |
| Dosage | 2 DOSAGE AND ADMINISTRATION The recommended dose is 150 mg of medroxyprogesterone acetate injectable suspension every 3 months (13 weeks) administered by deep, intramuscular (IM) injection in the gluteal or deltoid muscle. ( 2.1 ) 2.1 Prevention of Pregnancy The 1 mL vial of medroxyprogesterone acetate injectable suspension should be vigorously shaken just before use to ensure that the dose being administered represents a uniform suspension. The recommended dose is 150 mg of medroxyprogesterone |
| Warnings | WARNING: LOSS OF BONE MINERAL DENSITY Women who use medroxyprogesterone acetate injectable suspension may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible [see Warnings and Precautions (5.1) ] . It is unknown if use of medroxyprogesterone acetate injectable suspension during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture |
| Active ingredient(s) | MEDROXYPROGESTERONE ACETATE |
| Route | INTRAMUSCULAR |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0476eac5-d96c-4910-aa86-1ddeeefefe50 |